A fundamental challenge in drug development is the balance between optimizing a drug's lock-and-key fit with its target and the drug's ability to make its way across the cellular membrane and access that target.
Finding precise techniques to assess a treatment's or medication's efficacy is a significant difficulty when testing new therapies for people with intellectual disabilities.
Migraines are a pain in the head and in the hip pocket, but newly discovered genetic causes by QUT researchers could lead the way to new preventative drugs and therapies.
A variety of intricate cancer therapies known as antibody-drug conjugates (ADCs) have undergone clinical testing and been approved for use on patients. To explain the possible risks associated with these medications, researchers have conducted an extensive analysis of different scientific da
Adolescence is a time of significant skeletal development. One of the most universal, and sometimes distressing, experiences during adolescence is the development of acne a skin condition that results from the plugging of hair follicles with oil and dead skin cells. For some individuals whos
A protein that can predict whether or not DNA-damaging treatments will be effective when it is found in high concentrations in breast cancer tumors, according to researchers.
A team coaxed stem cells to take on the characteristics and functions of a human adrenal gland, progress that could lead to new therapies for adrenal insufficiencies and a deeper understanding of the genetics of such disorders.
ADCs, or antibody drug conjugates, are a class of complicated cancer treatments that have undergone extensive testing in clinical studies. The study explained the potential hazards related to these drugs.
In the brains of people with Alzheimer's disease, the protein amyloid- clumps together. The eventual deposition of these aggregates as so-called plaques results in damage to the brain's blood vessels and tissue
The protein medin is deposited in the blood vessels of the brains of Alzheimer's patients along with the protein amyloid-b. Researchers from DZNE have discovered this so-called co-aggregation. They have now published their observation in the renowned journal Nature. "Medin has been known for
New research suggests that adopting some of the strategies behind successfully treating the childhood disease of spinal muscular atrophy may enable the development of therapies to curb the muscle decline that accompanies aging.